NCT04214119 EsophaCap for the Detection of Early Esophageal Carcinoma
| NCT ID | NCT04214119 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | Barrett Esophagus |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2016-01-12 |
| Primary Completion | 2028-12-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,500 participants in total. It began in 2016-01-12 with a primary completion date of 2028-12-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is to identify potential biomarkers for the early detection of Barrett's Esophagus, esophageal carcinoma (both adenocarcinoma and squamous cell carcinoma), and gastric cancer via sponge cytology.
Eligibility Criteria
Inclusion Criteria: * Undergoing esophagogastroduodenoscopy at Johns Hopkins Hospital from 1/2016 to 12/2025 * Age greater than 18 years * Patients must be able to swallow a capsule Exclusion Criteria: * Patients in either arm with extra-esophageal malignancies including head and neck and gastric cancer * Patients who have undergone esophagectomy * Patients who have undergone radiation to the chest * Patients who are younger than 18 * Patients with esophageal stents * Patients with esophageal strictures disabling passage of the capsule
Contact & Investigator
Stephen Meltzer, M.D.
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT04214119 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Barrett Esophagus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04214119 currently recruiting?
Yes, NCT04214119 is actively recruiting participants. Contact the research team at smeltzer@jhmi.edu for enrollment information.
Where is the NCT04214119 trial being conducted?
This trial is being conducted at Baltimore, United States, Baltimore, United States.
Who is sponsoring the NCT04214119 clinical trial?
NCT04214119 is sponsored by Johns Hopkins University. The principal investigator is Stephen Meltzer, M.D. at Johns Hopkins University. The trial plans to enroll 2,500 participants.